Breast cancer therapy and bone

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ji P, Gong Y, Jin M-L, et al. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study. Front Oncol. 2017;10:650.
   Google Scholar
• Bidoli E, Virdone S, Hamdi-Cherif M, et al. Worldwide age at onset of female breast cancer: a 25-year population-based cancer registry study. Sci Rep. 2019;9(1):14111.
   PubMedGoogle Scholar
• Hamood R, Hamood H, Merhasin I, et al. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. Osteoporos Int. 2019;30(1):187–200.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.
   PubMed Web of Science ®Google Scholar
• Handforth C, d’oronzo S, Coleman R, et al. Cancer treatment and bone health. Calcif Tissue Int. 2018;102(2):251–264.
   PubMed Web of Science ®Google Scholar
• Greep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;114(8):653–659.
   PubMed Web of Science ®Google Scholar
• Zmuda JM, Cauley JA, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst. 2001;93(12):930–936.
   PubMedGoogle Scholar
• Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336(9):611–617.
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Sauter NP. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005;104(3):443–456.
   PubMed Web of Science ®Google Scholar
• Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2012;30(30):3665–3674.
   PubMed Web of Science ®Google Scholar
• Ramchand SK, Cheung Y, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111–R124.
   PubMed Web of Science ®Google Scholar
• Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2013;11 Suppl 3:S1–S50; quiz S51.
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–1223.
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306–3311.
   PubMed Web of Science ®Google Scholar
• Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90(9):704–708.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Välimäki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15(4):1341–1347.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15(3):955–962.
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. JCO. 1996;14(1):78–84.
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT, et al. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat. 1996;39(3):321–326.
   PubMed Web of Science ®Google Scholar
• Shapiro CL. Management of osteoporosis in women with breast cancer. Breast Cancer Management. 2020;9(2):BMT40.
   Web of Science ®Google Scholar
• Hadji P, Aapro MS, Body J-J, et al. Management of aromatase Inhibitor-Associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2017;7:1–12.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4057.
   PubMed Web of Science ®Google Scholar
• Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev. 2008;34:S1–S18.
   PubMed Web of Science ®Google Scholar
• Coleman R, Hadji P, Body J-J, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1650–1663.
   PubMed Web of Science ®Google Scholar
• Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. J Womens Health (Larchmt). 2014;23(7):563–572.
   PubMed Web of Science ®Google Scholar
• Trémollieres FA, Ceausu I, Depypere H, et al. Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas. 2017;95:65–71.
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture intervention trial. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab. 2000;85(11):4118–4124.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822.
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) Study group. Osteoporos Int. 2000;11(1):83–91.
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249.
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339–351.
   PubMed Web of Science ®Google Scholar
• Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. JCO. 2007;25(7):820–828.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. JCO. 2008;26(29):4739–4745.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. JCO. 2007;25(7):829–836.
   PubMed Web of Science ®Google Scholar
• Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405.
   PubMed Web of Science ®Google Scholar
• SEER Stat Fact Sheets: Breast Cancer. [cited 2019 Apr 15]. http://seer.cancer.gov/statfacts/html/breast.html.
   Google Scholar
• Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev. 2008;34 Suppl 1 (1):S3–S18.
   PubMedGoogle Scholar
• Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363(21):2027–2035.
   PubMed Web of Science ®Google Scholar
• Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21 Suppl 7:vii180–vii185.
   PubMed Web of Science ®Google Scholar
• Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat. 2004;87(2):181–188.
   PubMed Web of Science ®Google Scholar
• Fuleihan GE-H, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(6):3209–3214.
   PubMed Web of Science ®Google Scholar
• Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001;37(18):2373–2378.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13(5):503–514.
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14(19):6336–6342.
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. JCO. 2010;28(6):967–975.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77–85.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118(1):81–87.
   PubMed Web of Science ®Google Scholar
• Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112(5):1001–1010.
   PubMed Web of Science ®Google Scholar
• Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast. 2006;15 Suppl 1:S30–S40.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. JCO. 2008;26(16):2644–2652.
   PubMed Web of Science ®Google Scholar
• Safra T, Bernstein-Molho R, Greenberg J, et al. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology. 2011;81(5–6):298–305.
   PubMed Web of Science ®Google Scholar
• Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009;117(3):603–609.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Amir E, Paterson A, et al. Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. J Bone Oncol. 2015;4(2):54–58.
   PubMed Web of Science ®Google Scholar
• Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(18):2062–2081.
   PubMed Web of Science ®Google Scholar
• Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27(3):379–390.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353.
   PubMed Web of Science ®Google Scholar
• O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–443.
   PubMed Web of Science ®Google Scholar
• Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase III trial. Lancet Oncol. 2020;21(1):60–72.
   PubMed Web of Science ®Google Scholar